Oncology Central

Promising Phase I trial for anti-HER2 antibody

0
A Phase I trial of bispecific antibody ZW25, which binds to two regions on HER2 receptors simultaneously, was tolerated well and demonstrated a good response in patients with HER2-driven cancers such as those of the gullet or bowel.

Trastuzumab (Herceptin®) is currently the only approved HER2-targeting agent, and is quite effective for breast and stomach cancers. However, for patients with other cancers caused by HER2, there are no approved anti-HER2 agents, and for those with recurring HER2-positive breast or stomach cancer there are no other options.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.